{"id":"W3171490265","doi":"10.1200/jco.2021.39.15_suppl.tps9590","title":"NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Melanoma; Nivolumab; Immunotherapy; Oncology; CD8; Ipilimumab; Internal medicine; Blockade; Cancer; Cancer research; Immunology; Immune system; Receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001833168,0.002195587,0.002027005,0.0006543523,0.0006189517,0.001298996,0.001517116,0.001886079,0.007461378],"category_scores_gemma":[0.0008241943,0.0009333591,0.00127497,0.0005544184,0.001035557,0.001096227,0.0004122224,0.003482153,0.002231003],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001808557,"about_ca_system_score_gemma":0.00238529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00239328,"about_ca_topic_score_gemma":0.007864929,"domain_scores_codex":[0.9995232,0.0002199067,0.0000207145,0.00007875555,0.00005474427,0.0001028175],"domain_scores_gemma":[0.9994969,0.00006208254,0.0001018361,0.00002509457,0.00002854701,0.0002854519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6384674,0.1438642,0.01253368,0.002046344,0.001930459,0.0008128782,0.0006255464,0.003809075,0.06311577,0.0007042003,0.01519751,0.1168929],"study_design_scores_gemma":[0.5636433,0.4141009,0.01278016,0.0000644527,0.0003821919,0.0004344709,0.0001110886,0.001330273,0.002342256,0.0002092227,0.004551814,0.00004992754],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784424,0.003029519,0.0005805078,0.0009619881,0.0002792796,0.009205984,0.00343666,0.0002052277,0.003858519],"genre_scores_gemma":[0.9760463,0.002362126,0.002083003,0.001855501,0.000287734,0.006338788,0.004118361,0.00005939512,0.006848983],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007461378,"threshold_uncertainty_score":0.02496076,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08066561788258836,"score_gpt":0.4514859548832125,"score_spread":0.3708203370006241,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}